PIK3CA and neoplasm: Arguably, the divergent response type is the most exciting for personalised treatment, since it may identify cases where independent drug action and synergy may guide effective drug combinations.21 Here exemplified, we showed that PI3K inhibitors combined with either BRAF or MEK inhibitors increase in vitro synergy and reduce tumour volume of in vivo models.